3.9 Editorial Material

The adverse events of chemotherapy for retinoblastoma - What are they? Do we know?

Journal

ARCHIVES OF OPHTHALMOLOGY
Volume 126, Issue 6, Pages 862-865

Publisher

AMER MEDICAL ASSOC
DOI: 10.1001/archopht.126.6.862

Keywords

-

Categories

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

3.9
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

Low-grade glioma: A rare second tumor in retinoblastoma survivors

Nagma Dalvi, Ruth A. Kleinerman, Sidnei Epelman, David H. Abramson, Ira J. Dunkel

Summary: Survivors of hereditary retinoblastoma with RB1 gene mutations may have an increased risk for developing low-grade glioma, as shown by a retrospective review of databases from Memorial Sloan Kettering Cancer Center and the NCI.

PEDIATRIC BLOOD & CANCER (2021)

Article Oncology

Retinoblastoma management in 13q deletion syndrome patients using super-selective chemotherapies and other cancer-directed interventions

Lucy V. Cobbs, Jasmine H. Francis, Ira J. Dunkel, Y. Pierre Gobin, Scott E. Brodie, David H. Abramson

Summary: This study aimed to identify best practices for treating 13q deletion syndrome patients with retinoblastoma using super-selective ophthalmic artery chemosurgery and intravitreal injection therapy. The majority of patients treated with these regimens had good ocular survival rates, but there were increased risks of systemic complications. Despite toxicities, the majority of patients had good outcomes with acceptable toxicity levels.

PEDIATRIC BLOOD & CANCER (2021)

Article Oncology

General cancer screening practices among adult survivors of retinoblastoma: Results from the Retinoblastoma Survivor Study

Joanne F. Chou, Jennifer S. Ford, Ruth A. Kleinerman, David H. Abramson, Jasmine H. Francis, Charles A. Sklar, Kevin C. Oeffinger, Leslie L. Robison, Ira J. Dunkel, Danielle Novetsky Friedman

Summary: The study found that most Rb survivors adhere to cancer screening recommendations and the rates are not significantly different from non-Rb controls. Among female Rb survivors, utilization of Pap smear for cervical cancer screening is associated with older age, overweight/obesity, and lack of recent contact with medical personnel. Future research is needed to further explore these associations for potential intervention.

PEDIATRIC BLOOD & CANCER (2021)

Article Oncology

Molecular Changes in Retinoblastoma beyond RB1: Findings from Next-Generation Sequencing

Jasmine H. Francis, Allison L. Richards, Diana L. Mandelker, Michael F. Berger, Michael F. Walsh, Ira J. Dunkel, Mark T. A. Donoghue, David H. Abramson

Summary: By sequencing enucleated retinoblastoma specimens, this study found correlations between vitreous seeding and copy number variations, as well as between BCOR mutations and propensity for metastasis. Additionally, a portion of patients were found to have additional germline mutations in other cancer-related genes.

CANCERS (2021)

Article Ophthalmology

Pachydermoperiostosis Presenting With Vision Loss Secondary to Severe Phlyctenular Keratoconjunctivitis

Shuk Kei Cheng, Anika Michael, Allison E. Rizzuti

Summary: We report a rare case of severe phlyctenular keratoconjunctivitis associated with pachydermoperiostosis (PDP). To our knowledge, this is the first case of PDP to initially present with vision loss.

CORNEA (2022)

Article Oncology

Intensive Multimodality Therapy for Extraocular Retinoblastoma: A Children's Oncology Group Trial (ARET0321)

Ira J. Dunkel, Jin Piao, Guillermo L. Chantada, Anuradha Banerjee, Sherif Abouelnaga, Jeffrey C. Buchsbaum, Thomas E. Merchant, Meaghan M. Granger, Rima F. Jubran, Joanna L. Weinstein, Lauren Saguilig, David H. Abramson, Mark D. Krailo, Carlos Rodriguez-Galindo, Murali M. Chintagumpala

Summary: Intensive multimodality therapy is highly effective for patients with regional extraocular retinoblastoma and stage IVa metastatic retinoblastoma. However, more effective therapy is still required for patients with CNS involvement.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Article Oncology

Lack of complete response pretransplant is not associated with inferior overall survival for stage 4a metastatic retinoblastoma

Sameer Farouk Sait, Mauricio Rendon Bernot, Elizabeth Klein, David H. Abramson, Jasmine H. Francis, Stephen Gilheeney, Matthias A. Karajannis, Barbara Spitzer, Suzanne Wolden, Ira J. Dunkel, Nancy A. Kernan

Summary: Stage 4a metastatic RB patients treated with ASCT achieved similar overall survival regardless of pretransplant chemotherapy response. Furthermore, the administration of IFRT did not seem necessary for controlling bony disease and increased the risk of osteosarcoma.

PEDIATRIC BLOOD & CANCER (2023)

Article Genetics & Heredity

Biochemical measures of ovarian function in female survivors of retinoblastoma treated with intra-arterial melphalan: an initial report

Priya H. Marathe, Ira J. Dunkel, Jasmine H. Francis, Zoltan Antal, Y. Pierre Gobin, David H. Abramson, Danielle N. Friedman

Summary: This study assesses ovarian function in pubertal female survivors of retinoblastoma treated with melphalan-based OAC, and provides initial evidence that ovarian function remains intact.

OPHTHALMIC GENETICS (2022)

Article Multidisciplinary Sciences

Mutant-RB1 circulating tumor DNA in the blood of unilateral retinoblastoma patients: What happens during enucleation surgery: A pilot study

David H. Abramson, Diana L. Mandelker, A. Rose Brannon, Ira J. Dunkel, Ryma Benayed, Michael F. Berger, Maria E. Arcila, Marc Ladanyi, Danielle Novetsky Friedman, Gowtham Jayakumaran, Monica S. Diosdado, Melissa A. Robbins, Dianna Haggag-Lindgren, Neerav Shukla, Michael F. Walsh, Prachi Kothari, Dana W. Y. Tsui, Jasmine H. Francis

Summary: Cell free DNA (cfDNA) and circulating tumor cell free DNA (ctDNA) from blood (plasma) are increasingly used in oncology for various purposes. In this study, ctDNA was investigated in retinoblastoma patients at different stages of treatment, and it was found that the levels of ctDNA RB1 significantly decreased after optic nerve transection.

PLOS ONE (2023)

Article Ophthalmology

Cell-free RB1 DNA not detected in the blood of pseudoretinoblastoma patients

David H. Abramson, Diana Mandelker, A. Rose Brannon, Michael F. Berger, Melissa Robbins, Ira J. Dunkel, Jasmine H. Francis

Summary: The study aims to determine if RB1 ctDNA can be detected in the blood of patients with pseudoretinoblastoma, potentially aiding clinicians in the diagnosis of retinoblastoma.

BMJ OPEN OPHTHALMOLOGY (2022)

Article Oncology

Nivolumab with or without ipilimumab in pediatric patients with high-grade CNS malignancies: Safety, efficacy, biomarker, and pharmacokinetics-CheckMate 908

Ira J. Dunkel, Francois Doz, Nicholas K. Foreman, Darren Hargrave, Alvaro Lassaletta, Nicolas Andre, Jordan R. Hansford, Tim Hassall, Matthias Eyrich, Sridharan Gururangan, Ute Bartels, Amar Gajjar, Lisa Howell, Deepti Warad, Misena Pacius, Rachel Tam, Yu Wang, Li Zhu, Kenneth Cohen

Summary: The CheckMate 908 study evaluated the use of NIVO and NIVO + IPI in pediatric patients with high-grade CNS malignancies. The results showed that these treatments did not provide significant clinical benefits compared to historical data, but they had manageable safety profiles.

NEURO-ONCOLOGY (2023)

Article Oncology

Slipped capital femoral epiphyses: A major on-target adverse event associated with FGFR tyrosine kinase inhibitors in pediatric patients

Sameer Farouk Sait, Cheryl Fischer, Zoltan Antal, Krisoula Spatz, Daniel E. Prince, Katarzyna Ibanez, Gerald G. Behr, Ira J. Dunkel, Matthias A. Karajannis

Summary: Off label use of fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors (TKIs) in pediatrics is increasing. Limited long-term safety data and specific toxicities in pediatrics may arise. A retrospective analysis of patients under 18 years old with recurrent/refractory FGFR altered gliomas treated with FGFR TKIs at MSKCC (n = 7) showed slipped capital femoral epiphyses in three of seven patients along with increased linear growth velocity. Clinicians should closely monitor bone health and be aware of the potential for serious orthopedic complications, such as slipped capital femoral epiphyses, in pediatric patients receiving FGFR TKI treatment.

PEDIATRIC BLOOD & CANCER (2023)

Article Hematology

Dabrafenib, alone or in combination with trametinib, in BRAF V600-mutated pediatric Langerhans cell histiocytosis

James A. Whitlock, Birgit Geoerger, Ira J. Dunkel, Michael Roughton, Jeea Choi, Lisa Osterloh, Mark Russo, Darren Hargrave

Summary: Langerhans cell histiocytosis (LCH) is a rare neoplastic disorder primarily affecting children, and BRAF mutations are common in LCH patients. Dabrafenib, either alone or in combination with trametinib, has shown clinical efficacy and manageable toxicity in relapsed/refractory BRAF V600-mutant pediatric LCH. These findings suggest that dabrafenib-based therapies could be a potential treatment option for this patient group.

BLOOD ADVANCES (2023)

Article Oncology

A multi-institutional feasibility study of intra-arterial chemotherapy in children with retinoblastoma. A Children's Oncology Group study (COG ARET12P1)

Murali Chintagumpala, Jin Piao, Dan Gombos, Patricia Chevez-Barrios, Lindsay Brock, Ira J. Dunkel, Rima Jubran, Ann M. Leahey, Jonathan Kim, Joan O'Brien, Carol L. Shields, Carlos Rodriguez-Galindo

Summary: This study examined the feasibility of delivering melphalan directly into the ophthalmic artery for the treatment of retinoblastoma. The results showed that the treatment did not meet the feasibility goals, with a certain failure rate. The study suggests that centers planning to use this treatment should undergo training or refer patients to centers with expertise.

PEDIATRIC BLOOD & CANCER (2023)

Article Oncology

Chemotherapy-induced thrombocytopenia in pediatric oncology: Scope of the problem and opportunities for intervention

Melanie D. Degliuomini, Katherine Armstrong, Audrey Mauguen, Emily K. Slotkin, Stephen S. Roberts, Ira J. Dunkel, Mary Clouser, Michael Ortiz, Gerald A. Soff

Summary: This single-institution study examined the impact of chemotherapy-induced thrombocytopenia (CIT) on pediatric solid tumor cohorts. The results showed that CIT increased platelet transfusion burden and led to treatment reduction and delay.

PEDIATRIC BLOOD & CANCER (2022)

No Data Available